Patterns of chromosomal alterations in breast ductal carcinoma in situ

Clinical Cancer Research

Volumn 10, Issue 15, 2004, Pages 5160-5167

  Hwang, E Shelley ^a,b   DeVries, Sandy ^b   Chew, Karen Lo ^b   Moore II, Dan H ^b,c   Kerlikowske, Karla ^a   Thor, Ann ^d   Ljung, Britt Marie ^a,b   Waldman, Frederic M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^d UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER INVASION; CARCINOMA IN SITU; CHROMOSOMAL INSTABILITY; CHROMOSOME 17Q; CHROMOSOME 8Q; CHROMOSOME ABERRATION; CHROMOSOME DISORDER; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CHROMOSOMAL INSTABILITY; CHROMOSOME ABERRATIONS; CHROMOSOME MAPPING; CHROMOSOMES; DNA; FEMALE; HUMANS; MIDDLE AGED; MODELS, GENETIC; NEOPLASM INVASIVENESS; NUCLEIC ACID HYBRIDIZATION; PREVALENCE; PROGNOSIS; TIME FACTORS;

EID: 4143087052     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0165     Document Type: Article

References (44)

1. Ernster VL, Barclay J, Kerlikowske K, Gracy D, Henderson C. Incidence of and treatment for ductal carcinoma in situ of the breast [see comments]. J Am Med Assoc 1996;275:913-8.
2. Eusebi V, Feudale E, Foschini MP, et al. Long term follow-up of in situ carcinoma of the breast. Semin Diagn Pathol 1994;11:223-35.
3. Page DL, Dupont WD, Rogers LW, Jensen RA, Schuyler PA. Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer (Phila.) 1995;76:1197-200.
4. Radford DM, Phillips NJ, Fair KL, Ritter JH, Holt M, Donis-Keller H. Allelic loss and the progression of breast cancer. Cancer Res 1995;55:5180-3.
5. O'Connell P, Pekkel V, Fuqua SA, Osborne CK, Clark GM, Allred DC. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst (Bethesda) 1998;90:697-703.
6. Fujii H, Szumel R, Marsh C, Zhou W, Gabrielson E. Genetic progression, histological grade, and allelic loss in ductal carcinoma in situ of the breast. Cancer Res 1996;56:5260-5.
7. Waldman FM, DeVries S, Chew KL, Moore DH II, Kerlikowske K, Ljung BM. Chromosomal alterations in ductal carcinomas in situ and their in situ recurrences. J Natl Cancer Inst (Bethesda) 2000;92:313-20.
8. Nishizaki T, DeVries S, Chew K, et al. Genetic alterations in primary breast cancers and their metastases: direct comparison using modified comparative genomic hybridization. Genes Chromosomes Cancer 1997;19:267-72.
9. Nishizaki T, Chew K, Chu L, et al. Genetic alterations in lobular breast cancer by comparative genomic hybridization. Int J Cancer 1997;74:513-7.
10. Thor AD, Eng C, Devries S, et al. Invasive micropapillary carcinoma of the breast is associated with chromosome 8 abnormalities detected by comparative genomic hybridization. Hum Pathol 2002;33:628-31.
11. Waldman FM, Hwang ES, Etzell J, et al. Genomic alterations in tubular breast carcinomas, Hum Pathol 2001;32:222-6.
12. Consensus Conference on the classification of ductal carcinoma in situ. The Consensus Conference Committee. Cancer (Phila.) 1997;80:1798-802.
13. Piper J, Rutovitz D, Sudar D, et al. Computer image analysis of comparative genomic hybridization. Cytometry 1995;19:10-26.
14. Farabegoli F, Champeme MH, Bieche I, et al. Genetic pathways in the evolution of breast ductal carcinoma in situ. J Pathol 2002;196:280-6.
15. Holland R, Peterse JL, Millis RR, et al. Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol 1994;11:167-80.
16. Tabar L, Fagerberg G, Chen HH, Duffy SW, Gad A. Tumour development, histology and grade of breast cancers: prognosis and progression. Int J Cancer 1996;66:413-9.
17. Lennington WJ, Jensen RA, Dalton LW, Page DL. Ductal carcinoma in situ of the breast. Heterogeneity of individual lesions. Cancer (Phila.) 1994;73:118-24.
18. Buerger H, Otterbach F, Simon R, et al. Comparative genomic hybridization of ductal carcinoma in situ of the breast evidence of multiple genetic pathways. J Pathol 1999;187:396-402.
19. Kerlikowske K, Molinaro A, Cha I, et al. Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy J Natl Cancer Inst (Bethesda) 2003;95:1692-702.
20. Bijker N, Peterse JL, Duchateau L, et al. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma in situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol 2001;19:2263-71.
21. Fisher ER, Dignam J, Tan-Chiu E, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma. Cancer (Phila.) 1999;86:429-38.
22. Aldaz CM, Chen T, Sahin A, Cunningham J, Bondy M. Comparative allelotype of in situ and invasive human breast cancer: high frequency of microsatellite instability in lobular breast carcinomas. Cancer Res 1995;55:3976-81.
23. Radford DM, Fair KL, Phillips NJ, et al. Allelotyping of ductal carcinoma in situ of the breast: deletion of loci on 8p, 13q, 16q, 17p and 17q. Cancer Res 1995;55:3399-405.
24. James LA, Mitchell EL, Menasce L, Varley JM. Comparative genomic hybridisation of ductal carcinoma in situ of the breast: identification of regions of DNA amplification and deletion in common with invasive breast carcinoma. Oncogene 1997;14:1059-65.
25. Vos CB, ter Haar NT, Rosenberg C, et al. Genetic alterations on chromosome 16 and 17 are important features of ductal carcinoma in situ of the breast and are associated with histologic type. Br J Cancer 1999;81:1410-8.
26. Buerger H, Mommers EC, Littmann R, et al. Correlation of morphologic and cytogenetic parameters of genetic instability with chromosomal alterations in in situ carcinomas of the breast. Am J Clin Pathol 2000;114:854-9.
27. Gong G, DeVries S, Chew KL, Cha I, Ljung BM, Waldman FM. Genetic changes in paired atypical and usual ductal hyperplasia of the breast by comparative genomic hybridization. Clin Cancer Res 2001;7:2410-4.
28. Roylance R, Gorman P, Harris W, et al. Comparative genomic hybridization of breast tumors stratified by histological grade reveals new insights into the biological progression of breast cancer. Cancer Res 1999;59:1433-6.
29. Etzell JE, Devries S, Chew K, et al. Loss of chromosome 16q in lobular carcinoma in situ. Hum Pathol 2001;32:292-6.
30. Tsuda H, Takarabe T, Hirohashi S. Correlation of numerical and structural status of chromosome 16 with histological type and grade of non-invasive and invasive breast carcinomas. Int J Cancer 1999;84:381-7.
31. Tsuda H, Takarabe T, Fukutomi T, Hirohashi S. der(16)t(1;16)/der(1;16) in breast cancer detected by fluorescence in situ hybridization is an indicator of better patient prognosis. Genes Chromosomes Cancer 1999;24:72-7.
32. Flagiello D, Gerbault-Seureau M, Sastre-Garau X, Padoy E, Vielh P, Dutrillaux B. Highly recurrent der(1;16)(q10;p10) and other 16q arm alterations in lobular breast cancer. Genes Chromosomes Cancer 1998;23:300-6.
33. Haagensen CD, Lane N, Bodian C. Coexisting lobular neoplasia and carcinoma of the breast. Cancer (Phila.) 1983;51:1468-82.
34. Bednarek AK, Laflin KJ, Daniel RL, Liao Q, Hawkins KA, Aldaz CM. WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res 2000;60:2140-5.
35. Yaremko ML, Recant WM, Westbrook CA. Loss of heterozygosity from the short arm of chromosome 8 is an early event in breast cancers. Genes Chromosomes Cancer 1995;13:186-91.
36. Welm BE, Freeman KW, Chen M, Contreras A, Spencer DM, Rosen JM. Inducible dimerization of FGFRI: development of a mouse model to analyze progressive transformation of the mammary gland. J Cell Biol 2002;157:703-14.
37. Ni CY, Murphy MP, Golde TE, Carpenter G. gamma-Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science (Wash. DC) 2001;294:2179-81.
38. Isola J, Chu L, DeVries S, et al. Genetic alterations in ERBB2-amplified breast carcinomas. Clin Cancer Res 1999;5:4140-5.
39. Boland GP, McKeown A, Chan KC, Prasad R, Knox WF, Bundred NJ. Biological response to hormonal manipulation in oestrogen receptor-positive ductal carcinoma in situ of the breast. Br J Cancer 2003;89:277-83.
40. Lebeau A, Unholzer A, Amann G, et al. EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast. Breast Cancer Res Treat 2003;79:187-98.
41. Jacobs JJ, Keblusek P, Robanus-Maandag E, et al. Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19(ARF)) and is amplified in a subset of human breast cancers. Nat Genet 2000;26:291-9.
42. Zhao R, Gish K, Murphy M, et al. Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev 2000;14:981-93.
43. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-11.
44. Adimoolam S, Ford JM. p53 and regulation of DNA damage recognition during nucleotide excision repair. DNA Repair (Amst.) 2003;2:947-54.